Results 1 to 10 of about 15,024 (164)

Breakthrough Advances in Beta-Lactamase Inhibitors: New Synthesized Compounds and Mechanisms of Action Against Drug-Resistant Bacteria

Pharmaceuticals
Beta-lactam drugs hold a central place in the antibacterial arsenal, and the production of beta-lactamases by drug-resistant bacteria has severely compromised the effectiveness of nearly all available beta-lactams.
Ya-Si Huang, Hong Zhou
doaj   +3 more sources

The known-unknown: third- and fourth-generation cephalosporins combined with sulbactam [PDF]

Клиническая микробиология и антимикробная химиотерапия, 2023
Despite the presence of more than 100 different antibacterials in the therapeutic arsenal, beta-lactam antibiotics, in general, and the third-generation cephalosporins, in particular, remain the main option for the treatment of the most of infections in ...
Stetsiouk O.U., Kovalenko T.N., Andreeva I.V., Belkova Yu.A.   +3 more
doaj   +1 more source

Antibiotic use in Australian and Swedish primary care: a cross-country comparison

Scandinavian Journal of Primary Health Care, 2022
Objective Antimicrobial resistance is a growing worldwide problem and is considered to be one of the biggest threats to global health by the World Health Organization.
Konny Andersson, Mieke van Driel, Katarina Hedin, Samantha Hollingworth, Gregory Merlo   +4 more
doaj   +1 more source

Beta-Lactamase Repressor BlaI Modulates Staphylococcus aureus Cathelicidin Antimicrobial Peptide Resistance and Virulence. [PDF]

, 2015
BlaI is a repressor of BlaZ, the beta-lactamase responsible for penicillin resistance in Staphylococcus aureus. Through screening a transposon library in S.
Gallo, Richard L, Haste, Nina M, Kristian, Sascha A, Meharena, Hiruy S, Nizet, Victor, Olson, Joshua, Pence, Morgan A   +6 more
core   +9 more sources

Clinical Outcomes of Non-carbapenem Treatment for Urinary Tract Infections Caused by Extended-spectrum β-lactamase-producing [PDF]

Childhood Kidney Diseases, 2021
Purpose The purpose of this study was to investigate the clinical outcomes of non-carbapenem treatment for urinary tract infections (UTIs) caused by extended-spectrum β-lactamase (ESBL)-producing Escherichia coli (E. coli) in young children.
Eunae Kim, Yo Han Ahn, Jung Won Lee, Eujin Park   +3 more
doaj   +1 more source

Treatment in Infections by Enterobacterales Producing Extended Spectrum Betalactamase. Systematic Review

Kasmera, 2021
Extended spectrum beta-lactamases producing Enterobacterales have become pandemic worldwide representing a major public health threat due to poor outcomes and high mortality associated with infections by these bacteria, consequently it is essential to ...
Carli Samira Aziz Delgado, José Andrés Mendoza Gaviria   +1 more
doaj   +1 more source

Inverse association between use of broad spectrum penicllin with beta-lactamase inhibitors and prevalence of type 1 diabetes mellitus in Europe

Scientific Reports, 2021
Increasing incidence of type 1 diabetes is supposed to be induced by environmental factors. Microbiome modulated by antibiotics seems to serve as one of the environmental factors which could influence the development of T1DM.
Gábor Ternák, Károly Berényi, Szilárd Kun, Nóra Szigeti, Tamás Decsi, Gábor Sütő, István Wittmann   +6 more
doaj   +1 more source

Functional Dynamics of Substrate Recognition in TEM Beta-Lactamase

Entropy, 2022
The beta-lactamase enzyme provides effective resistance to beta-lactam antibiotics due to substrate recognition controlled by point mutations. Recently, extended-spectrum and inhibitor-resistant mutants have become a global health problem.
Chris Avery, Lonnie Baker, Donald J. Jacobs   +2 more
doaj   +1 more source

Neutralizing Carbapenem Resistance by Co-Administering Meropenem with Novel β-Lactam-Metallo-β-Lactamase Inhibitors

Antibiotics, 2023
Virulent Enterobacterale strains expressing serine and metallo-β-lactamases (MBL) genes have emerged responsible for conferring resistance to hard-to-treat infectious diseases. One strategy that exists is to develop β-lactamase inhibitors to counter this
Nakita Reddy, Letisha Girdhari, Mbongeni Shungube, Arnoldus C. Gouws, Byron K. Peters, Kamal K. Rajbongshi, Sooraj Baijnath, Sipho Mdanda, Thandokuhle Ntombela, Thilona Arumugam, Linda A. Bester, Sanil D. Singh, Anil Chuturgoon, Per I. Arvidsson, Glenn E. M Maguire, Hendrik G. Kruger, Thavendran Govender, Tricia Naicker   +17 more
doaj   +1 more source

Variations in the SDN Loop of Class A Beta-Lactamases: A Study of the Molecular Mechanism of BlaC (Mycobacterium tuberculosis) to Alter the Stability and Catalytic Activity Towards Antibiotic Resistance of MBIs

Frontiers in Microbiology, 2021
The emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis calls for an immediate search for novel treatment strategies.
Sourya Bhattacharya, Vivek Junghare, Niteesh Kumar Pandey, Subhecchha Baidya, Harsha Agarwal, Neeladrisingha Das, Ayan Banerjee, Ayan Banerjee, Debashish Ghosh, Debashish Ghosh, Partha Roy, Hirak K. Patra, Saugata Hazra, Saugata Hazra   +13 more
doaj   +1 more source